The one year survival rate of lung adenocarcinoma patients treated with chemotherapy or targeted therapy
| Autor: | Erwin Arief, Fidiyah Rusdi, Harun Iskandar, Tutik Hardjianti, Hasyim Kasim, Syakib Bakri, Wasis Udaya, Arifin Seweng |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Targeted therapy 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine Lung cancer Prospective cohort study Survival rate General Nursing Chemotherapy Lung business.industry General Medicine respiratory system medicine.disease respiratory tract diseases medicine.anatomical_structure 030220 oncology & carcinogenesis Adenocarcinoma Erlotinib business medicine.drug |
| Zdroj: | Enfermería Clínica. 30:456-460 |
| ISSN: | 1130-8621 |
| DOI: | 10.1016/j.enfcli.2019.10.120 |
| Popis: | Background Adenocarcinoma is the most common of lung Cancer. The treatment for early stage of lung Adenocarcinoma (I, II) is surgery. Targeted therapy is given to lung Adenocarcinoma patients with EGFR-TKI mutations. Chemotherapy is given to lung Adenocarcinoma patients without EGFR-TKI mutations. Objective To compare one-year survival of lung Adenocarcinoma patients treated with chemotherapy or targeted therapy. Methods This was a prospective study. The subjects were 100 patients with lung Adenocarcinoma. Results 1-year Survival of lung Adenocarcinoma patient for one year was 18%. 1-year survival in patients with targeted therapy was higher than chemotherapy, which was 24% vs 9% (p 0.05). 1-Year survival in patients with Erlotinib drug was 45% highest survival rate compared to chemotherapy drugs and other targeted therapy (p Conclusion Lung Adenocarcinoma patients receiving Erlotinib significantly had the highest survival rate compared to all other targeted therapy drugs and all types of chemotherapy drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|